Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 1, January, p. 79–84

doi: 10.17219/acem/111820

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities

Katarzyna Maria Chyl-Surdacka1,A,B,C,D, Joanna Bartosińska1,A,C,D, Małgorzata Kowal1,B,C, Joanna Przepiórka-Kosińska1,B, Dorota Krasowska1,E,F, Grażyna Chodorowska1,A,C,E,F

1 Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Poland


Background. Visfatin is one of the pro-inflammatory adipokines secreted by adipose tissue cells. Recent scientific research has drawn attention to the role of adipokines in the pathophysiology of metabolic disorders and their association with inflammatory diseases, including psoriasis. Visfatin may be one of the important links explaining the connection between psoriasis and diseases which are components of metabolic syndrome.
Objectives. The aim of this study was to assess the serum visfatin concentration in patients with psoriasis and to evaluate its possible correlations with parameters of metabolic syndrome and the clinical severity of psoriasis.
Material and Methods. A group of 102 patients with psoriasis and a control group of 40 healthy subjects were examined. The clinical severity of psoriasis was assessed according to Psoriasis Area and Severity Index), BSA (Body Surface Area) and DLQI (Dermatology Life Quality Index) indicators, the presence and type of obesity, and hypertension. In both the study and control groups, laboratory tests (C-reactive protein (CRP), glucose concentration, total cholesterol, low-density-lipoprotein (LDL) cholesterol, high-density-lipoprotein (HDL) cholesterol, and triglycerides (TG)) were performed and serum visfatin concentrations were determined. The clinical data, results of laboratory tests and visfatin concentrations were then subjected to statistical analysis.
Results. There was a significantly higher concentration of visfatin in the psoriatic patients (p < 0.001) than in the control group. Significant positive correlations between visfatin concentration and PASI (p = 0.008) and BSA (p = 0.007) were observed. In the psoriatic group, there were positive correlations between the concentrations of visfatin and the concentrations of CRP (p = 0.008) and total cholesterol (p = 0.002). Visfatin concentration was elevated in the psoriatic patients who had elevated total cholesterol (p = 0.001), LDL cholesterol (p = 0.012) and TG levels (p = 0.001) compared to the psoriatic patients with normal levels of these lipid profile components.
Conclusion. The results indicate the possible participation of visfatin in pathophysiological and inflammatory processes in the course of psoriasis. Adipokines may be an important link connecting psoriasis with coexisting metabolic disorders.

Key words

psoriasis, visfatin, metabolic syndrome

References (40)

  1. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: The missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12–25.
  2. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54(10):2911–2916.
  3. Carbone F, Liberale L, Bonaventura A, et al. Regulation and function of extracellular nicotinamide phosphoribosyltransferase/visfatin. Compr Physiol. 2017;7(2):603–621.
  4. Hognogi LD, Simiti LV. The cardiovascular impact of visfatin – an inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016;89(3):322–326.
  5. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: An adipokine with cardiovascular impact. Mediators Inflamm. 2013;2013:946427.
  6. Saboori S, Hosseinzadeh-Attar MJ, Yousefi Rad E, Hosseini M, Mirzaei K, Ahmadivand Z. The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab Syndr. 2015;9(4):320–323.
  7. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: Parallel increase in plasma visfatin. J Clin Endocrinol Metab. 2006;91(12):5022–5028.
  8. Ziora K, Oświęcimska J, Świętochowska E, et al. Stężenie wisfatyny w surowicy krwi u dziewcząt z otyłością prostą. Endokrynol Pediatr. 2011;10(2):17–25.
  9. Bułdak RJ, Polaniak R, Kukla M, Żwirska-Korczala K. Wisfatyna: enzym, cytokina czy adipokina? Funkcje biologiczne wisfatyny in vitro. 2011.
  10. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–50763.
  11. Uslu S, Kebapçi N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012;4(1):113–120.
  12. Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357(1):150–156.
  13. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angio­genesis. Cardiovasc Res. 2008;78(2):356–365.
  14. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2292–2301.
  15. Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond). 2009;33(4):465–472.
  16. Liu SW, Qiao SB, Yuan JS, Liu DQ. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res. 2009;41(4):281–286.
  17. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748–1758.
  18. Romacho T, Azcutia V, Vázquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52(11):2455–2463.
  19. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81(2):370–380.
  20. Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection? Curr Opin Pharmacol. 2009;9(2):202–207.
  21. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105(5):481–491.
  22. Wang P, Xu TY, Guan YF, et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 2011;69(2):360–374.
  23. Ismail SA, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol. 2012;167(2):436–439.
  24. Okan G, Baki AM, Yorulmaz E, Doğru-Abbasoğlu S, Vural P. Serum visfatin, fetuin-A, and pentraxin 3 levels in patients with psoriasis and their relation to disease severity. J Clin Lab Anal. 2016;30(4):284–289.
  25. Campanati A, Ganzetti G, Giuliodori K, et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: Results of a retrospective analysis. Int J Dermatol. 2015;54(7):839–845.
  26. Sereflican B, Goksugur N, Bugdayci G, Polat M, Haydar Parlak A. Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-α) levels in patients with psoriasis and their correlation with disease severity. Acta Dermatovenerol Croat. 2016;24(1):13–19.
  27. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis. 2011;21(4):245–253.
  28. Lu YC, Hsu CC, Yu TH, et al. Association between visfatin levels and coronary artery disease in patients with chronic kidney disease. Iran J Kidney Dis. 2013;7(6):446–452.
  29. Coban M, Tasli L, Turgut S, Özkan S, Tunç Ata M, Akın F. Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann Dermatol. 2016;28(1):74–79.
  30. Ozal E, Sahin I, Bolat I, et al. Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy. Blood Press Monit. 2017;22(3):137–142.
  31. Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A. Visfatin in juvenile obesity: The effect of obesity intervention and sex. Eur J Clin Invest. 2011;41(12):1284–1291.
  32. Li RZ, Ma Xn, Hu XF, et al. Elevated visfatin levels in obese children are related to proinflammatory factors. J Pediatr Endocrinol Metab. 2013;26(1–2):111–118.
  33. Reda R, Shehab A, Soliman D, Gabr A, Abbass A. Serum visfatin levels in a group of Egyptian obese individuals. Egypt J Immunol. 2011;18(1):25–32.
  34. Salama HM, Galal A, Motawie AA, et al. Adipokines vaspin and visfatin in obese children. Maced J Med Sci. 2015;3(4):563–566.
  35. Taşkesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol. 2012;4(2):76–81.
  36. Coban M, Tasli L, Turgut S, Özkan S, Tunç Ata M, Akın F. Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann Dermatol. 2016;28(1):74–79.
  37. Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, et al. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly: Results from the PolSenior substudy. J Am Soc Hypertens. 2015;9(1):1–8.
  38. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: Association with cholesterol levels in women. Metabolism. 2007;56(9):1216–1220.
  39. Fadaei R, Parvaz E, Emamgholipour S, et al. The mRNA expression and circulating levels of visfatin and their correlation with coronary artery disease severity and 25-hydroxyvitamin D. Horm Metab Res. 2016;48(4):269–274.
  40. Liakos CI, Sanidas EA, Perrea DN, et al. Apelin and visfatin plasma levels in healthy individuals with high normal blood pressure. Am J Hypertens. 2016;29(5):549–552.